The 2012 discovery of CRISPR-Cas9, a revolutionary gene editing tool, embroiled scientists, ethicists, policymakers, and patient advocates in seemingly intractable conversations regarding the moral, social, and political implications of editing DNA. Simultaneously, the regulatory and governance environment into which t...
It is argued that achieving the potential of AI in oncology clinical trials will require rigorous prospective validation, harmonized regulatory standards, and coordination among clinicians, trialists, regulators, industry and patients.
Andrea Villa, A. Eadie, David Synnott et al.· Nature Reviews Clinical Onco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.